|Table of Contents|

Label-free quantitative proteomics and phosphoproteomics analysis of clear cell renal cell carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 04
Page:
617-622
Research Field:
Publishing date:

Info

Title:
Label-free quantitative proteomics and phosphoproteomics analysis of clear cell renal cell carcinoma
Author(s):
Gulinaizaier Abudusaimaiti1; DUAN Shuangshuang1; LIU Huibin2
1.Department of Pharmacy，Xinjiang Medical University，Xinjiang Urumqi 830011，China；2.Clinical Trials Center，Affiliated Tumor Hospital of Xinjiang Medical University，Xinjiang Urumqi 830011，China.
Keywords:
proteomics; phosphoproteomics; clear cell renal cell carcinoma; bioinformatics analysis
PACS:
R737.11
DOI:
10.3969/j.issn.1672-4992.2024.04.005
Abstract:
Objective:To utilize phosphoproteomics and proteomics combined analysis techniques to identify differentially expressed proteins related to the pathogenesis of clear cell renal cell carcinoma (ccRCC) and discover novel diagnosis and treatment targets for ccRCC.Methods:We selected cancer tissue and adjacent tissue samples from 30 ccRCC patients who underwent urological surgery at the Affiliated Tumor Hospital of Xinjiang Medical University between January 2017 to December 2020.Label-free quantitative proteomics and phosphorylation modification techniques were used to analyze the differentially expressed proteins and phosphorylation modification sites.Bioinformatics analyzed the key protein kinases,phosphorylation sites and signaling pathways.Results:A total of 2 552 differentially expressed total proteins,3 024 differentially expressed phosphorylation sites and 1 572 phosphorylated proteins corresponding to them were identified by the combined histological analysis strategy.Functional enrichment and clustering analysis showed that the differentially phosphorylated proteins were mainly involved in important signaling pathways such as ErbB signaling pathway,VEGF signaling pathway,and cell adhesion pathway,among which PDHK1,NDR1,NDR2 and MST1 might become novel candidate markers and drug targets.Conclusion:The expression levels of total protein and phosphorylated protein in ccRCC and normal tissues next to cancer are significantly different,which is expected to be a potential research application direction for precision diagnosis and treatment of ccRCC.

References:

［1］ COUTO-CUNHA A，JERONIMO C，HENRIQUE R.Circulating tumor cells as biomarkers for renal cell carcinoma：ready for prime time［J］.Cancers (Basel)，2022，15(1)：287.
［2］ CHU G，XU T，ZHU G，et al.Identification of a novel protein-based signature to improve prognosis prediction in renal clear cell carcinoma［J］.Front Mol Biosci，2021，8：623120.
［3］ RASSY E，FLIPPOT R，ALBIGES L.Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma［J］.Ther Adv Med Oncol，2020，12：175883592090750.
［4］ SANDIN V，PEREIRA DDE A，KALUME DE，et al.Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma［J］.Urol Oncol，2016，34(1)：5.e11-25.
［5］ LI Y，YANG B，MA Y，et al.Phosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinoma［J］.Signal Transduct Target Ther，2021，6(1)：381.
［6］ AYALA-AGUILERA CC，VALERO T，LORENTE-MACAS ，et al.Small molecule kinase inhibitor drugs (1995-2021):Medical indication,pharmacology,and synthesis［J］.J Med Chem，2022，65(2)：1047-1131.
［7］ COLES GL，CRISTEA S，WEBBER JT，et al.Unbiased proteomic profiling uncovers a targetable GNAS/PKA/PP2A axis in small cell lung cancer stem cells［J］.Cancer Cell，2020，38(1)：129-143.
［8］ DU S，ZHONG Y，ZHENG S，et al.Analysis and prediction of the survival trends of patients with clear-cell renal cell carcinoma:a model-based period analysis,2001-2015［J］.Cancer Control，2022，29:10732748221121226.
［9］ QU Y，FENG J，WU X，et al.A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population［J］.Nat Commun，2022，13(1)：2052.
［10］ ELIU X，QUAN J，SHEN Z，et al.Metallothionein 2A (MT2A) controls cell proliferation and liver metastasis by controlling the MST1/LATS2/YAP1 signaling pathway in colorectal cancer［J］.Cancer Cell Int，2022，22(1)：205.
［11］ GUO C，LIANG C，YANG J，et al.LATS2 inhibits cell proliferation and metastasis through the Hippo signaling pathway in glioma［J］.Oncol Rep，2019，41(5)：2753-2761.
［12］ JIAO Y，LI Y，JIANG P，et al.High MAST2 mRNA expression and its role in diagnosis and prognosis of liver cancer［J］.Sci Rep，2019，9(1)：19865.
［13］ LU H，LU Y，XIE Y，et al.Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma［J］.JCI Insight，2019，4(19)：e131106.
［14］ 朱利红，段树鹏，秦海霞，等.miR-198靶向MAPK1调控宫颈癌HeLa细胞增殖、凋亡和侵袭［J］.肿瘤防治研究，2018，12：959-964. ZHU LH，DUAN SP，QIN HX，et al.miR-198 targets MAPK1 to regulate proliferation,apoptosis and invasion of cervical cancer HeLa cells ［J］.Cancer Research on Prevention and Treatment，2018，12：959-964.
［15］ SANG Y，KONG P，ZHANG S，et al.SGK1 in human cancer:emerging roles and mechanisms［J］.Front Oncol，2021，10：608722.
［16］ WANG R，XU K，GAO F，et al.Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer［J］.Biochim Biophys Acta Rev Cancer，2021，1876(2)：188590.
［17］ CLARK DJ,DHANASEKARAN SM,PETRALIA F,et al.Integrated proteogenomic characterization of clear cell renal cell carcinoma［J］.Cell，2019，179(4):964-983.
［18］ YANG Y,CAO Y.The impact of VEGF on cancer metastasis and systemic disease［J］.Semin Cancer Biol，2022，86(3)：251-261.
［19］ ATKINS MB，TANNIR NM.Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma［J］.Cancer Treat Rev，2018，70：127-137.
［20］ DRAGO JZ，FERRARO E，ABUHADRA N，et al.Beyond HER2:Targeting the ErbB receptor family in breast cancer［J］.Cancer Treat Rev，2022，9：102436.
［21］ LA MONICA S.EGFR signaling in non-small cell lung cancer:from molecular mechanisms to therapeutic opportunities［J］.Cells，2022，11(8)：1344.
［22］ WANG Z.ErbB receptors and cancer［J］.Methods Mol Biol，2017，1652：3-35.
［23］ CHU C，LU C，ZHANG Z，et al.Correlation of VEGF and EGFR in peripheral blood with clinical stage and pathological grade of renal cell carcinoma and analysis of prognosis［J］.J BUON，2018，23(4)：1097-1102.
［24］ COOPER AJ，SEQUIST LV，LIN JJ.Third-generation EGFR and ALK inhibitors:mechanisms of resistance and management［J］.Nat Rev Clin Oncol，2022，19(8)：499-514.

Memo

Memo:
新疆维吾尔自治区科技支疆项目计划(编号:2022E02131)
Last Update: 1900-01-01